

Fig 1 The structure of the Vaccibody.



Fig 2 Principle.




Fig 3 Flow cytometry of splenocytes




Fig 4 The NIP-specific control Vaccibodies exhibits binding to the hapten NIP.

5/25




Fig 5 The Vaccibodies exhibit binding to DNP, hence the antigenic scFv is correctly folded.

6/25




Fig 6 APC pulsed with titrated amounts of MHC class II specific Vaccibodies

7/25





Fig 7 The MHC class II-specific Vaccibodies induce a strong anti-Id Ab response in the absence of adjuvants.

8/25

A Short hinge



B long hinge




Fig 8 Construction of the two hinge-Cy3 variants of hIgG3 origin by PCR.

9/25




Fig 9 Construction of the hinge-C γ 3 segments derived from mIgG2b.

10/25




Fig 10 Construction of the scFv derived from the myeloma protein M315.

11/25




Fig 11 Joining of the hinge-C γ 3 segments and the M315 scFv by PCR soeing.

12/25




Fig 12 Subcloning of the hinge-C γ 3-M315 scFv into pUC19.

13/25




Fig 13 Removal of two inconvenient BamHI restriction enzyme sites by QuickChange PCR.

14/25




Fig 14 Introduction of stop codon, a SfiI and a BamHI restriction enzyme site downstream of the coding region by QuickChange PCR.

15/25




Fig 15 Subcloning into the C cassette of the expression vector pLNOH₂ on HindII-BamHI

16/25




Fig 16 Cloning of the V regions specific for NIP and MHCII and assembling into a scFv format by PCR soeing.

17/25




Fig 17 Subcloning into the expression vector pLNOH₂ on BsmI/MunI and BsiWI

18/25




Fig 18 The final Vaccibody construct.

19/25




Fig 19 The Vaccibody gene construct

20/25




Fig 20 Vaccibodies are secreted as functional molecules.

21/25




Fig 21 Production of Vaccibodies by intramucular injection of naked DNA plasmids followed by *in vivo* electroporation

22/25




Fig 22 Tumor avoidance.

23/25




Fig 23 Induction of protective immunity against the MOPC315.4 plasmacytoma.

24/25




Fig 24 Level of M315 myeloma protein in sera of mice on a) day 18 and b) day 24 after MOPC315.4 challenge.

25/25




Fig 25 Chemokine Vaccibodies are secreted as functional molecules.